IN8bio
INAB | NASDAQ
$0.77
-$0.05 (-6.10%)
At close: Nov 16, 2026, 3:59 PM ET
$0.80
+$0.03 (+3.86%)
After-hours:
Nov 16, 2026, 7:52 PM ET
-6.10%
(1D)No price chart data available for 1D timeframe.
Rating
34.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #667/1021 (Top 65%)
Key Statistics
Market Data
Market Cap $14.99M
1D Range
0.72 1.02
52W Range
0.72 2.59
Valuation (TTM)
PE -0.61
PB 1.06
EV/EBITDA -0.21
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $4.00
Cash Flow
FCF Yield -100.0%
SBC Adj. FCF Yield -112.4%
SBC Impact -12.4%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 104.9% |
50.6%
FCF 3Y | 5Y 27.9% |
13.2%
Returns
ROA -103.8%
ROE -93.7%
ROIC -115.7%
Financial Health
Net Cash
$11.22M
Current Ratio 5.78
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various for...
Sector Healthcare
Industry Biotechnology
Employees 18
IPO Date Jul 30, 2021
Website in8bio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$4.00
Upside
+419.48%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove INAB